TY - JOUR
T1 - Applications of immunopharmacogenomics
T2 - Predicting, preventing, and understanding immune-mediated adverse drug reactions
AU - Karnes, Jason H.
AU - Miller, Matthew A.
AU - White, Katie D.
AU - Konvinse, Katherine C.
AU - Pavlos, Rebecca K.
AU - Redwood, Alec J.
AU - Peter, Jonathan G.
AU - Lehloenya, Rannakoe
AU - Mallal, Simon A.
AU - Phillips, Elizabeth J.
PY - 2019/1/6
Y1 - 2019/1/6
N2 - Adverse drug reactions (ADRs) are a significant health care burden. Immune-mediated adverse drug reactions (IM-ADRs) are responsible for one-fifth of ADRs but contribute a disproportionately high amount of that burden due to their severity. Variation in human leukocyte antigen (HLA) genes has emerged as a potential preprescription screening strategy for the prevention of previously unpredictable IM-ADRs. Immunopharmacogenomics combines the disciplines of immunogenomics and pharmacogenomics and focuses on the effects of immune-specific variation on drug disposition and IM-ADRs. In this review, we present the latest evidence for HLA associations with IM-ADRs, ongoing research into biological mechanisms of IM-ADRs, and the translation of clinical actionable biomarkers for IM-ADRs, with a focus on T cell-mediated ADRs.
AB - Adverse drug reactions (ADRs) are a significant health care burden. Immune-mediated adverse drug reactions (IM-ADRs) are responsible for one-fifth of ADRs but contribute a disproportionately high amount of that burden due to their severity. Variation in human leukocyte antigen (HLA) genes has emerged as a potential preprescription screening strategy for the prevention of previously unpredictable IM-ADRs. Immunopharmacogenomics combines the disciplines of immunogenomics and pharmacogenomics and focuses on the effects of immune-specific variation on drug disposition and IM-ADRs. In this review, we present the latest evidence for HLA associations with IM-ADRs, ongoing research into biological mechanisms of IM-ADRs, and the translation of clinical actionable biomarkers for IM-ADRs, with a focus on T cell-mediated ADRs.
KW - Adverse drug reaction
KW - Human leukocyte antigen
KW - Immunopharmacogenomics
KW - Pharmacogenomics
KW - Stevens-Johnson syndrome
KW - Toxic epidermal necrolysis
UR - http://www.scopus.com/inward/record.url?scp=85057352696&partnerID=8YFLogxK
U2 - 10.1146/annurev-pharmtox-010818-021818
DO - 10.1146/annurev-pharmtox-010818-021818
M3 - Review article
C2 - 30134124
AN - SCOPUS:85057352696
SN - 0362-1642
VL - 59
SP - 463
EP - 486
JO - Annual Review of Pharmacology and Toxicology
JF - Annual Review of Pharmacology and Toxicology
ER -
